Research programme: monoclonal antibody therapeutics - Ganymed

Drug Profile

Research programme: monoclonal antibody therapeutics - Ganymed

Alternative Names: Anti-CLDN18.2 bispecific antibody - Ganymed Pharmaceuticals; Anti-CLDN18.2 drug conjugate - Ganymed Pharmaceuticals; Anti-CLDN6 bispecific antibody - Ganymed Pharmaceuticals; Anti-CLDN6 drug conjugate - Ganymed Pharmaceuticals

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ganymed Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Claudin 18 protein inhibitors; Claudin 6 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Solid tumours

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for research development in Breast-cancer in Germany (Parenteral)
  • 28 Mar 2018 No recent reports of development identified for research development in Solid-tumours in Germany (Parenteral)
  • 21 Dec 2016 Ganymed Pharmaceuticals has been acquired by Astellas Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top